Berenberg Bank Boosts Hikma Pharmaceuticals (LON:HIK) Price Target to GBX 2,560

Hikma Pharmaceuticals (LON:HIK) had its price objective increased by analysts at Berenberg Bank from GBX 2,400 ($29.88) to GBX 2,560 ($31.87) in a note issued to investors on Wednesday,Digital Look reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s price target points to a potential upside of 12.28% from the stock’s current price.

Hikma Pharmaceuticals Stock Performance

Shares of LON HIK traded up GBX 32 ($0.40) during trading on Wednesday, hitting GBX 2,280 ($28.39). The company had a trading volume of 1,778,026 shares, compared to its average volume of 1,237,701. The stock has a 50 day simple moving average of GBX 2,001.97 and a 200 day simple moving average of GBX 1,947.80. The firm has a market capitalization of £5.06 billion, a P/E ratio of 3,507.69, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.48, a quick ratio of 1.27 and a current ratio of 1.66. Hikma Pharmaceuticals has a 12 month low of GBX 1,750 ($21.79) and a 12 month high of GBX 2,290 ($28.51).

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.